Type 1 diabetes complicated by chronic kidney disease (CKD) is associated with substantial renal and cardiovascular risk, yet treatment options remain limited. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated cardiorenal benefits in type 2 diabetes, but its efficacy and safety in type 1 diabetes are not well established. To address this, a study evaluated finerenone in 242 participants with type 1 diabetes and CKD.
The study found that over 6 months, urinary albumin-to-creatinine ratio decreased by 34% with finerenone compared with 12% with placebo, corresponding to a 25% greater reduction with finerenone versus placebo. Median urinary albumin-to-creatinine ratio declined from 574.6 to 373.5 with finerenone and from 506.4 to 475.6 with placebo. Estimated glomerular filtration rate changed by -5.6 mL/min/1.73 m² with finerenone versus -2.7 mL/min/1.73 m²…
